Under the terms of the deal, Stemcell will distribute Cellular Dynamics' iCell line of induced pluripotent stem cell products.
The firm will use MaxCyte's cell transfection platform to edit hematopoietic stem cells with CRISPR/Cas9 in hemoglobinopathy and SCID.
Researchers found evidence that mutations and age-related methylation signatures tend to persist in induced pluripotent stem cells from the elderly.
The cell lines were edited with CRISPR/Cas9 to create fusions of GFP with the proteins of interest, allowing researchers to image structures in real time.
The researchers said their one-step, inducible, multiplex gene knockdown and gene knockout platforms can be used in many differentiated cell types.
Thermo Fisher said the deal strengthens its portfolio for stem cell research, and it will fold MTI-GlobalStem into its life sciences solutions segment.
The companies will work together to develop human induced pluripotent stem cell-derived cardiomyocytes and neurons for use in drug discovery.
By analyzing the transcriptomes of more than 4,000 individual cells, researchers identified stem cell-like cellular subpopulations in six oligodendroglioma tumors.
A new study suggests CRISPR/Cas9-based gene activation can manipulate particular epigenomic patterns found in differentiated cells.
The grant from the California Institute of Regenerative Medicine will fund research on two approaches to DMD gene therapy using CRISPR/Cas9.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.